This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jiangsu Hengrui Medicine Co., Ltd.
Drug Names(s): henatinib maleate
Description: Henatinib is an orally bioavaiable small molecule that inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis.
Additional information available to subscribers only: